Journal articles produced by the DSU and its network, broken down into topics.
E Poku, J Rathbone, R Wong, E Everson-Hock, M Essat, A Pandor, A Wailoo. The safety of intravitreal bevacizumab monotherpay in adult ophthalmic conditions: systematic review. 2014 BMJ Open 4:e005244. DOI: 10.1136/bmjopen-2014-005244
A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: Cost-effectiveness evidence and NICE guidance: Reply Rheumatology 2008; Vol 47 (10): 1590.
A Wailoo, N Bansback, J Chilcott. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: Cost-effectiveness evidence and NICE guidance Rheumatology 2008; Vol 47 (2): 119-120.
A Wailoo, A Sutton, A Morgan. The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: A systematic review and meta-analysis 2009 British Journal of Cancer Vol 100: 436-441.
S Lloyd, S Bujkiewicz, A Wailoo, A Sutton, D Scott. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: A systematic review and meta-analysis. Rheumatology 2010; Vol 49 (12): 2313-2321.
A. Scope, A. Bhadhuri and B. Pennington (2022) "Systematic review of cost-utility analyses that have included carer and family member health-related quality of life". Value in Health. DOI: https://doi.org/10.1016/j.jval.2022.02.008
Rowen D, Mukuria C, Powell P A, Wailoo A. "Exploring the issues of valuing child and adolescent health states using a mixed sample of adolescents and adults". PharmacoEconomics, Accepted: 24 January 2022, Online 16/03/2022.
Laura A Gray, Monica Hernandez Alava and Allan J Wailoo (2021) Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer 21:1237 DOI: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08964-5
A review of the psychometric performance of selected child and adolescent preference-based measures used to generate utility values for children. Value in Health 2020; ISSN 1098-3015; DOI: https://doi.org/10.1016/j.jval.2020.09.012
J Hill, D Rowen, R Pennington, A Wailoo, R Wong (2020) A review of the methods used to generate utility values in NICE technology assessments for children and adolescents. Value in Health, 2020, 23(7): 907-917. DOI: https://doi.org/10.1016/j.jval.2020.02.011
EQ5DMAP: A command for mapping between 3-level and 5-level EQ-5D (August 2018). To install the command within Stata use "ssc install eq5dmap".
The impact of moving from EQ-5D-3L to -5L in NICE Technology Appraisals (August 2018).
EQ-5D-5L versus EQ-5D-3L: The impact on cost-effectiveness in the United Kingdom (October 2017).
S E Grimm, M Strong, A Brennan et al. (January 2016) Framework for analysing risk in health technology assessments and its application to managed entry agreements (PDF, 1.5MB).
S E Grimm, M Strong, A Brennan et al. (2017) The HTA risk analysis chart: Visualising the need for and potential value of managed entry agreements in health technology assessment. PharmacoEconomics 35: 1287.
M Hernández Alava, A Wailoo. ALDVMM: A command for fitting adjusted limited dependent variable mixture models to EQ-5D. The Stata Journal 2015 In press. Available online.
B Pennington, S Davis (December 2014) Mapping from the health assessment questionnaire to the EQ-5D: The impact of different algorithms on cost-effectiveness results. Value in Health 17(8):762-771.
K K Shah, A Tsuchiya, A Wailoo (2015) Valuing health at the end of life: A stated preference discrete choice experiment. Social Science and Medicine; 124:48-56 (first published online November 2014).
M Hernández Alava, A Wailoo, F Wolfe, K Michaud (2014) A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Medical Decision Making; 34: 919-930 (first published online 2013 DOI: 10.1177/0272989X13500720).
O Ciani, S Davis, P Tappenden, R Garside, K Stein, A Cantrell, E D Saad, M Buse, R S Taylor (2014) Validation of surrogate endpoints in advanced solid tumors: Systematic review of statistical methods, results, and implications for policy makers. International Journal of Technology Assessment in Health Care; 30(3): 312-324.
K K Shah, A Tsuchiya, A Wailoo (2014) Valuing health at the end of life: An empirical study of public preferences. European Journal of Health Economics; 15(4): 389-399 (first published online May 2013; DOI: 10.1007/s10198-013-0482-3).
B Kearns, R Ara, A Wailoo, A Manca, M Hernandez Alava, K Abrams, M Campbell (2013) Good practice guidelines for the use of statistical regression models in economic evaluations. PharmacoEconomics; 31(8): 643-652.
P Thokala, A Duenas (2012) The applicability of multi criteria decision analysis for health technology assessment. Value in Health; 15(8): 1172-1181.
S Davis, A Wailoo (2013) A review of the psychometric performance of the EQ-5D in people with urinary incontinence. Health and Quality of Life Outcomes; 11(20).
K K Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: An exploratory preference elicitation study (PDF, 364KB). HEDS Discussion Paper 11/17.
J Morden, P Lambert, N Latimer, K Abrams, A Wailoo (2011) Assessing methods for dealing with treatment switching in randomised clinical trials: A simulation study BMC Medical Research Methodology; Vol 11:4.
A Wailoo, A Tsuchiya, C McCabe (2009) Weighting must wait: Incorporating equity concerns into cost-effectiveness analysis may take longer than expected. PharmacoEconomics; 27(12): 983-989.
A Wailoo, A Sutton, N Cooper, D Turner, K Abrams, A Brennan, K Nicholson (2008) Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value in Health; 11(2): 160-171.
Technical support documents
D Phillipo, A Ades, S Dias, S Palmer, K Abrams, N Welton (February 2018) Methods for population-adjusted indirect comparisons in health technology appraisals. Med Decis Making; 38(2): 200-211. DOI: 10.1177/0272989X17725740
S Dias, N Welton, A Sutton, A Ades (July 2013) Evidence synthesis for decision making 1: Introduction. Med Decis Making; 33: 597-606. DOI: 10.1177/0272989X13487604
S Dias, A Sutton, A Ades, N Welton (July 2013) Evidence synthesis for decision making 2: A Generalised linear modeling framework for pairwise and network meta-analysis of randomised controlled trials. Med Decis Making; 33: 607-617, first published on October 26, 2012. DOI: 10.1177/0272989X12458724
S Dias, A Sutton, N Welton, A Ades (July 2013) Evidence synthesis for decision making 3: Heterogeneity-subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making; 33: 618-640, DOI: 10.1177/0272989X13485157
S Dias, N Welton, A Sutton, D Caldwell, G Lu, A Ades (July 2013) Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomised controlled trials. Med Decis Making; 33: 641-656. DOI: 10.1177/0272989X12455847
S Dias, N Welton, A Sutton, A Ades (July 2013) Evidence synthesis for decision making 5: The baseline natural history model. Med Decis Making; 33: 657-670. DOI: 10.1177/0272989X13485155
S Dias, A Sutton, N Welton, A Ades (July 2013) Evidence synthesis for decision making 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis. Med Decis Making; 33: 671-678. DOI: 10.1177/0272989X13487257
A Ades, D Caldwell, S Reken, N Welton, A Sutton, S Dias (July 2013) Evidence synthesis for decision making 7: A reviewer’s checklist. Med Decis Making; 33: 679-691. DOI: 10.1177/0272989X13485156
Papaioannou, J Brazier, S Paisley (2013) Systematic searching and selection of health state utility values from the literature. Value in Health; 16(4): 686-695.
L Longworth, D Rowen (2013) Mapping to obtain EQ-5D utility values for use in NICE Health Technology Appraisals. Value in Health; 16(1): 202-210.
R Ara, A Wailoo (2012) Using health state utility values in models exploring the cost-effectiveness of health technologies. Value in Health; 15: 6.
N Latimer (2013) Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. Inconsistencies, limitations, and a practical guide. Medical Decision Making; 33(6): 743-754.
A Bagust, S Beale (2013). Survival analysis and extrapolation modeling of time-to-event clinical trail data for economic evaluation: An alternative approach. Medical Decision Making. DOI: 10.1177/0272989X13497998
N Latimer (2013). Response to “Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: An alternative approach” by Bagust and Beal. Medical Decision Making. DOI: 10.1177/0272989X13511302
Methods Guide update process 2008
A Miners (2008) Estimating ‘costs’ for cost-effectiveness analysis. PharmacoEconomics, 26(9): 745-751.
A Sutton, A E Ades, N Cooper, K Abrams, (2008) Use of indirect and mixed treatment comparisons for technology assessment. PharmacoEconomics, 26(9): 753-767.
M Sculpher (2008) Subgroups and heterogeneity in cost-effectiveness analysis. PharmacoEconomics, 26(9): 799-806.
C McCabe, K Claxton, A J Culyer (2008) The NICE cost-effectiveness threshold. What it is and what that means. PharmacoEconomics, 26(9): 733-744.
K Claxton (2008) Exploring uncertainty in cost-effectiveness analysis. PharmacoEconomics, 26: 781-798.
J Brazier (2008) Valuing health states for use in cost-effectiveness analysis. PharmacoEconomics, 26(9): 769-779.
A world top-100 university
We're a world top-100 university renowned for the excellence, impact and distinctiveness of our research-led learning and teaching.